

Form 154 – Breast Health Supplement to the Medication Inventory

HEALTH INITIATIVE	WHI Extension Stu	dy			
Date Received:	(MM/DD/YY)	- Affix label here- Participant ID: First NameM.I Last Name			
Contact Type: □ ₁ Phone □ ₂ Mail □ ₈ Other	Visit Type: □ ₃ Annual □ ₄ Non-Routine	\square FCA \square OUI \square OU2 Language: \square_1 English \square_2 Spanish			
	OFFICE USE ONL	Y			
Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0414). Do not return the completed form to this address.					
Instructions:					
To help us learn about the health of WHI participants, we would like to know more about some of the medications you may take. As part of your participation in the Women's Health Initiative, you previously reported a diagnosis of breast cancer or breast cancer in situ. This form asks about medications that you may have used to treat breast cancer.					
<u> </u>					

1-800-218-8415.

If you would like to have a WHI staff member at the Clinical Coordinating Center complete this form with you over the phone, please feel free to call

WHI Form 154 – Breast Health Supplement to the Medication Inventory WHI Extension Study

The first set of questions asks about medications known as **SERMS** (**selective estrogen receptor modulators**). These medications include tamoxifen (Nolvadex[®]), raloxifene (Evista[®]), and toremifene (Fareston[®]).

Ver. 1

Since your breast cancer diagnosis:

1.	Have you <u>ever</u> taken tamoxifen (Nolvadex [®])?
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	1.1 How long did you take or have you taken tamoxifen? (Use your best estimate; mark only one.) \square_1 Less than 1 month \square_4 1-2 years \square_2 1-5 months \square_5 3-4 years \square_3 6-11 months \square_6 5 or more years
2.	Have you <u>ever</u> taken raloxifene (Evista [®])?	
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	2.1 How long did you take or have you taken raloxifene? (Use your best estimate; mark only one.) \square_1 Less than 1 month \square_4 1-2 years \square_2 1-5 months \square_5 3-4 years \square_3 6-11 months \square_6 5 or more years
3.	Have you <u>ever</u> taken toremifene	(Fareston®)?
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	3.1 How long did you take or have you taken toremifene? (Use your best estimate; mark only one.) \square_1 Less than 1 month \square_4 1-2 years \square_2 1-5 months \square_5 3-4 years \square_3 6-11 months \square_6 5 or more years

Please go to next page

WHI Form 154 – Breast Health Supplement to the Medication Inventory WHI Extension Study

Ver. 1

These next questions ask about medications known as **anti-estrogen therapies** or **aromatase inhibitors**. These medications include anastrozole (Arimidex[®]), exemestane (Aromasin[®]), and letrozole (Femara[®]).

Since your breast cancer diagnosis:

4.	. Have you <u>ever</u> taken anastrozole (Arimidex ®)?			
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	4.1	How long did you take or hat (Use your best estimate; maximum \Box_1 Less than 1 month \Box_2 1-5 months \Box_3 6-11 months	ark only one.) $\square_4 \text{ 1-2 years}$ $\square_5 \text{ 3-4 years}$
5.	Have you ever taken exemestane	(Aro	omasin [®])?	
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	5.1	How long did you take or hat (Use your best estimate; m $\square_1 \text{ Less than 1 month}$ $\square_2 \text{ 1-5 months}$ $\square_3 \text{ 6-11 months}$	ark only one.) $\square_4 \text{ 1-2 years}$ $\square_5 \text{ 3-4 years}$
6.	Have you <u>ever</u> taken letrozole (Fe	emar	a [®])?	
	□ ₀ No □ ₁ Yes → □ ₉ Don't know	6.1	How long did you take or h (Use your best estimate; n $\square_1 \text{ Less than 1 month}$ $\square_2 \text{ 1-5 months}$ $\square_3 \text{ 6-11 months}$	mark only one.) $\square_4 \text{ 1-2 years}$ $\square_5 \text{ 3-4 years}$

Please go to next page

WHI Form 154 – Breast Health Supplement to the Medication Inventory Ver. 1 WHI Extension Study

7.	Have you <u>ever</u> taken any SERM or aromatase inhibitor that is not listed above, or that you may not recall the name of?				
	\prod_0 No				
	7.1 How long did you take or have you taken this medication? (Use your best estimate; mark only one.)				
	$\square_{1} \text{ Less than 1 month} \qquad \square_{4} \text{ 1-2 years}$				
	\square_2 1-5 months \square_5 3-4 years				
	\square_3 6-11 months \square_6 5 or more years				
8.	Have any of the following barriers prevented you from obtaining or taking the prescribed breast cancer medications previously asked about (i.e., tamoxifen, raloxifene, toremifene, anastrazole, exemestane, and letrozole)? (Please check all that apply.)				
	\square_1 I did not experience any barriers to taking these medications.				
	\square_2 I have never heard of these medications.				
	\square_3 My health insurance would not cover these medications.				
	\square_4 These medications or copayments cost too much.				
	\square_5 It is a problem for me to get to my medical facility/physician.				
	\square_6 Taking these medications would be inconvenient.				
	\square_7 I was concerned about possible side effects or complications from these medications.				
	\square_8 I was concerned about missing work due to taking these medications.				
	\square_9 My family discouraged me from taking these medications.				
	\square_{10} My friends discouraged me from taking these medications.				
	\square_{11} I am taking too many medications.				
	\square_{12} I don't like taking medications.				
	\square_{13} My physician did not recommend these medications for my particular type of breast disease \square_{14} Other:				
9.	What is the date you finished answering this form? Month Day Year				

Thank you.

Please take a moment to review any questions you may have missed.

WHI Form 154 – Breast Health Supplement to the Medication Inventory WHI Extension Study

Spanish translation underway

Ver. 1

FORM: 154 – BREAST CANCER PREVENTION AND TREATMENT MEDICATIONS

Version: 1 - November, 2008

Description: Self-administered or interviewer-administered; 3-page booklet; key-entered at the Clinical

Coordinating Center (CCC).

When used: Collected one time as part of the annual contacts for Clinical Trial (CT) and Observational Study (OS)

participants enrolled in the WHI Extension Study who have indicated a previous breast biopsy or

diagnosis of breast cancer on WHI Form 33/33D.

Purpose: To collect updated information on specific types of medications (SERMS and aromatase inhibitors)

currently being prescribed for the prevention and treatment of breast cancer.

GENERAL INSTRUCTIONS

1. The form is printed in both English (Form 154) and Spanish (Form 154S) versions.

- 2. The *Form 154* for WHI Extension Study participants will be labeled and mailed from the CCC directly to the participant. Form is only mailed to participants with a previous breast biopsy or diagnosis of breast cancer.
 - The CCC mails the form to the participant and asks her to mail it back in a return envelope by a specified date. Following the CCC mailing, if the participant does not return the *Form 153* within 3 months of the first mailing, it will be sent again. If the form is not returned within 2 months of the second mailing, the form will be sent a third time. If the form is still not returned, CCC staff will contact the participants by telephone to collect the information from willing participants. The CCC will data enter the forms.
- 3. In the event that this form is collected by FC staff, the form should be sent to the CCC for data entry.

Item Instructions

1.	Tamoxifen (Nolvadex) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q2.
1.1.	Tamoxifen – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
2.	Raloxifene (Evista) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q3.
2.1.	Raloxifene – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
3.	Toremifene (Fareston) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q4.
3.1.	Toremifene – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
4.	Anastrozole (Arimidex) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q5.
4.1.	Anastrozole – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
5.	Exemestane (Aromasin) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q6.
5.1.	Exemestane – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
6.	Letrozole (Femara) – Ever Taken	No/Yes/DK. Participants indicating "No" or "DK" skip to Q7.
6.1.	Letrozole – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
7.	Ever Taken Any Other SERM or Aromatase Inhibitor	No/Yes/DK. Participants indicating "No" or "DK" skip to Q8.
7.1.	Other SERM or Aromatase Inhibitor – Duration	Participant indicates length of time the medication was taken: 1. Less than 1 month; 2. 1-5 months; 3. 6-11 months; 4. 1-2 years; 5. 3-4 years; 6. 5 or more years.
8.	Barriers to Breast Cancer Medications	Check all that apply.